GeneDx Holdings Corp. shares fell 49% on May 5, 2026, after the company reported a significant Q1 2026 earnings miss, a tenfold increase in net loss, and cut its full-year 2026 revenue guidance by 12%. The company cited a shift in product mix toward genome tests, which have a lower average reimbursement rate, causing revenue growth to slow to at least 20%, down from the 33%-35% previously forecasted. This unexpected downturn wiped out over $900 million in market value in one day and triggered an investigation by shareholder rights law firm Hagens Berman into possible securities law violations. Investors who suffered losses are encouraged to contact the firm for potential legal action.
